OssDsign AB (publ) (OSSD.ST)
SEK 13.94
(-2.65%)
SEK 13.94
(-2.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -130.49 Million SEK | -31.3% |
| 2022 | -99.38 Million SEK | -5.82% |
| 2021 | -93.91 Million SEK | -11.03% |
| 2020 | -84.59 Million SEK | -0.41% |
| 2019 | -84.24 Million SEK | -50.41% |
| 2018 | -56.01 Million SEK | 11.48% |
| 2017 | -63.27 Million SEK | -121.89% |
| 2016 | -28.51 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -11.14 Million SEK | 79.29% |
| 2024 Q2 | -15.68 Million SEK | -40.73% |
| 2023 Q4 | -53.84 Million SEK | -62.54% |
| 2023 FY | -130.49 Million SEK | -31.3% |
| 2023 Q1 | -23.25 Million SEK | 27.22% |
| 2023 Q2 | -20.27 Million SEK | 12.8% |
| 2023 Q3 | -33.12 Million SEK | -63.37% |
| 2022 Q3 | -19.55 Million SEK | 18.28% |
| 2022 Q2 | -23.93 Million SEK | 0.09% |
| 2022 FY | -99.38 Million SEK | -5.82% |
| 2022 Q4 | -31.94 Million SEK | -63.36% |
| 2022 Q1 | -23.95 Million SEK | 16.62% |
| 2021 FY | -93.91 Million SEK | -11.03% |
| 2021 Q4 | -28.72 Million SEK | -73.77% |
| 2021 Q3 | -16.53 Million SEK | 34.74% |
| 2021 Q2 | -25.33 Million SEK | -8.59% |
| 2021 Q1 | -23.32 Million SEK | 6.5% |
| 2020 Q4 | -24.95 Million SEK | -33.15% |
| 2020 Q3 | -18.74 Million SEK | 17.03% |
| 2020 FY | -84.59 Million SEK | -0.41% |
| 2020 Q1 | -18.31 Million SEK | 36.56% |
| 2020 Q2 | -22.58 Million SEK | -23.34% |
| 2019 Q1 | -17.34 Million SEK | -3.34% |
| 2019 FY | -84.24 Million SEK | -50.41% |
| 2019 Q4 | -28.86 Million SEK | -46.46% |
| 2019 Q3 | -19.7 Million SEK | -7.52% |
| 2019 Q2 | -18.33 Million SEK | -5.71% |
| 2018 Q3 | -13.62 Million SEK | 4.87% |
| 2018 Q2 | -14.32 Million SEK | -26.91% |
| 2018 Q1 | -11.28 Million SEK | 0.0% |
| 2018 FY | -56.01 Million SEK | 11.48% |
| 2018 Q4 | -16.78 Million SEK | -23.15% |
| 2017 FY | -63.27 Million SEK | -121.89% |
| 2016 FY | -28.51 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | -67.645% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 226.08% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 226.08% |
| Arcoma AB | 2.56 Million SEK | 5189.431% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 5.701% |
| BICO Group AB (publ) | -835.7 Million SEK | 84.385% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 622.453% |
| CellaVision AB (publ) | 130.3 Million SEK | 200.141% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | -63.541% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -347.098% |
| C-Rad AB (publ) | 35.52 Million SEK | 467.286% |
| Duearity AB (publ) | -26.19 Million SEK | -398.255% |
| Dignitana AB (publ) | -17.36 Million SEK | -651.558% |
| Episurf Medical AB (publ) | -94.8 Million SEK | -37.651% |
| Getinge AB (publ) | 2.41 Billion SEK | 105.41% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | -91.966% |
| Iconovo AB (publ) | -45.89 Million SEK | -184.337% |
| Integrum AB (publ) | 4.03 Million SEK | 3336.05% |
| Luxbright AB (publ) | -25.37 Million SEK | -414.256% |
| Mentice AB (publ) | -2.81 Million SEK | -4532.339% |
| Paxman AB (publ) | 8.33 Million SEK | 1666.543% |
| Promimic AB (publ) | -9.22 Million SEK | -1315.018% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 18.419% |
| SciBase Holding AB (publ) | -55.58 Million SEK | -134.763% |
| ScandiDos AB (publ) | -14.64 Million SEK | -790.92% |
| Sectra AB (publ) | 428.38 Million SEK | 130.461% |
| Sedana Medical AB (publ) | -59.61 Million SEK | -118.904% |
| Senzime AB (publ) | -134.14 Million SEK | 2.725% |
| SpectraCure AB (publ) | -20.44 Million SEK | -538.389% |
| Stille AB | 26.64 Million SEK | 589.728% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 96.611% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 242.118% |